A Phase 1 Study of TRAIL-R2 (DR5) Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Trial Profile

A Phase 1 Study of TRAIL-R2 (DR5) Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs DS 8273 (Primary) ; Nivolumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 29 Sep 2017 Status changed from active, no longer recruiting to discontinued as per business decision
    • 10 Aug 2017 Planned End Date changed from 1 Dec 2018 to 22 Sep 2017.
    • 10 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 22 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top